Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025

Crinetics Pharmaceuticals, Inc.

2024-FY EPS reported -$3.69 revenue$1,039,000

Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.
Revenue fell to $1.0M in 2024 from $4.0M in 2023; no Q4 revenue.
Cash $1.4B at Dec 31, 2024, up from $558.6M; includes $925M in equity financings.
PDUFA target action date for paltusotine (acromegaly) set for Sept 25, 2025.
Plan to start Phase 3 paltusotine in carcinoid syndrome Q2 2025 and four IND filings in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.